TY - JOUR
T1 - Endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic heart failure
T2 - A randomized placebo-controlled trial (END-HF)
AU - Santoso, Teguh
AU - Siu, Ching Wah
AU - Irawan, Cosphiadi
AU - Chan, Wing Sze
AU - Alwi, Idrus
AU - Yiu, Kai Hang
AU - Aziz, Auda
AU - Kwong, Yok Lam
AU - Tse, Hung Fat
N1 - Funding Information:
Acknowledgments This study was supported by the S.K. Yee Medical Foundation Grant (208207); and Research Grant Council of Hong Kong: General Research Fund (no. HKU 780110M); the Collaborative Research Fund (HKU 8/CRF/09); and Theme Based Research Scheme (T12-705/11).
PY - 2014/8
Y1 - 2014/8
N2 - Prior studies suggest that endomyocardial implantation of autologous bone marrow (BM) mononuclear cell therapy improves symptoms and left ventricular (LV) function in patients with refractory angina; however, the therapeutic efficacy in patients with ischemic cardiomyopathy is unclear. In a randomized, double-blind, placebo-controlled trial, 28 patients with advanced ischemic cardiomyopathy [New York Heart Association III-IV, LV ejection fraction (LVEF) <40 %] were assigned in 2:1 ratio to receive endomyocardial injection of BM cells (100 million, n=19) or placebo (n=9), guided by electroanatomical mapping. After 6 months, there was no significant difference between the two groups in LV ejection fraction (LVEF) and LV end-systolic volume (LVESV), LV infarct volume, and LV peri-infarct ischemic volume as determined by cardiac magnetic resonance imaging or exercise capacity. In conclusion, endomyocardial implantation of autologous BM mononuclear cells did not improve LV function or remodeling in patients with advanced ischemic cardiomyopathy.
AB - Prior studies suggest that endomyocardial implantation of autologous bone marrow (BM) mononuclear cell therapy improves symptoms and left ventricular (LV) function in patients with refractory angina; however, the therapeutic efficacy in patients with ischemic cardiomyopathy is unclear. In a randomized, double-blind, placebo-controlled trial, 28 patients with advanced ischemic cardiomyopathy [New York Heart Association III-IV, LV ejection fraction (LVEF) <40 %] were assigned in 2:1 ratio to receive endomyocardial injection of BM cells (100 million, n=19) or placebo (n=9), guided by electroanatomical mapping. After 6 months, there was no significant difference between the two groups in LV ejection fraction (LVEF) and LV end-systolic volume (LVESV), LV infarct volume, and LV peri-infarct ischemic volume as determined by cardiac magnetic resonance imaging or exercise capacity. In conclusion, endomyocardial implantation of autologous BM mononuclear cells did not improve LV function or remodeling in patients with advanced ischemic cardiomyopathy.
KW - Bone marrow cells
KW - Heart failure
KW - Ischemic cardiomyopathy
UR - http://www.scopus.com/inward/record.url?scp=84906790563&partnerID=8YFLogxK
U2 - 10.1007/s12265-014-9580-6
DO - 10.1007/s12265-014-9580-6
M3 - Article
C2 - 25079593
AN - SCOPUS:84906790563
SN - 1937-5387
VL - 7
SP - 545
EP - 552
JO - Journal of Cardiovascular Translational Research
JF - Journal of Cardiovascular Translational Research
IS - 6
ER -